semaglutide + cagrilintide blend 1 CagriSema 2.4 mg /

Because these pathways are directly relevant to body-composition and obesity-related research, cagrilintide is commonly included in studies investigating appetite suppression, meal-related signaling, and the biological mechanisms that shape energy intake over time [1][3]

Follow-up Repeat broad markers after 6-12 weeks if symptoms change, inflammation is part of the context, or the protocol continues

Based on REDEFINE trial populations and the NDA submission terms, expected eligibility criteria are: BMI 30 , or BMI 27 with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea Adults 18 years or older Not pregnant or breastfeeding Contraindications will likely include: personal or family history of MTC or MEN 2 syndrome, prior serious allergic reaction to semaglutide or cagrilintide, and active pancreatitis

Long-term outcomes The 68-week clinical trial data provides the best window into long-term expectations